The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on August 31, 2023. The analyst firm set a price target for $86.00 expecting KROS to rise to within 12 months (a possible 163.80% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Wedbush, and Keros Therapeutics reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $86.00. The current price Keros Therapeutics (KROS) is trading at is $32.60, which is within the analyst’s predicted range.

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on August 31, 2023. The analyst firm set a price target for $86.00 expecting KROS to rise to within 12 months (a possible 163.80% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Wedbush, and Keros Therapeutics reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $86.00. The current price Keros Therapeutics (KROS) is trading at is $32.60, which is within the analyst’s predicted range.

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on August 31, 2023. The analyst firm set a price target for $86.00 expecting KROS to rise to within 12 months (a possible 163.80% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Wedbush, and Keros Therapeutics reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $86.00. The current price Keros Therapeutics (KROS) is trading at is $32.60, which is within the analyst’s predicted range.

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on August 31, 2023. The analyst firm set a price target for $86.00 expecting KROS to rise to within 12 months (a possible 163.80% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Wedbush, and Keros Therapeutics reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $86.00. The current price Keros Therapeutics (KROS) is trading at is $32.60, which is within the analyst’s predicted range.

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on August 31, 2023. The analyst firm set a price target for $86.00 expecting KROS to rise to within 12 months (a possible 163.80% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Wedbush, and Keros Therapeutics reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $86.00. The current price Keros Therapeutics (KROS) is trading at is $32.60, which is within the analyst’s predicted range.

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on August 31, 2023. The analyst firm set a price target for $86.00 expecting KROS to rise to within 12 months (a possible 163.80% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Wedbush, and Keros Therapeutics reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $86.00. The current price Keros Therapeutics (KROS) is trading at is $32.60, which is within the analyst’s predicted range.

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on August 31, 2023. The analyst firm set a price target for $86.00 expecting KROS to rise to within 12 months (a possible 163.80% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Wedbush, and Keros Therapeutics reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $86.00. The current price Keros Therapeutics (KROS) is trading at is $32.60, which is within the analyst’s predicted range.

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by Wedbush on August 31, 2023. The analyst firm set a price target for $86.00 expecting KROS to rise to within 12 months (a possible 163.80% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ: KROS) was provided by Wedbush, and Keros Therapeutics reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $86.00. The current price Keros Therapeutics (KROS) is trading at is $32.60, which is within the analyst’s predicted range.